Specific anti-gastric cancer effects of a recombinant plasmid expressing nonstructural protein 1 of parvovirus H1

Saudi Medical Journal

Volumn 35, Issue 4, 2014, Pages 336-345

  Zhao, Di ^a   Cai, Chenwen ^a   Wang, Yuanyuan ^a   Xiao, Shudong ^a   Zheng, Qing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN E; ENHANCED GREEN FLUORESCENT PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIPOFECTAMINE; MESSENGER RNA; NONSTRUCTURAL PROTEIN 1; NUCLEAR PROTEIN; PLASMID VECTOR; PROPIDIUM IODIDE; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RESTRICTION ENDONUCLEASE; RETINOBLASTOMA PROTEIN; NS1 PROTEIN, PARVOVIRUS; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA SEQUENCE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH CURVE; H-1 PARVOVIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPOSOMAL GENE DELIVERY SYSTEM; MALE; MOUSE; MRNA EXPRESSION ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; RADIOIMMUNOPRECIPITATION; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH TUMOR; TUMOR NECROSIS; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL CYCLE; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; NUDE MOUSE; PARVOVIRIDAE; PATHOLOGY; PLASMID; PROCEDURES; STOMACH NEOPLASMS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENETIC THERAPY; GENETIC VECTORS; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; PARVOVIRUS; PLASMIDS; RECOMBINANT PROTEINS; STOMACH NEOPLASMS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84899624156     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008. Cancer incidence and mortality worldwide. IARC CancerBase No. 10. Lyon (France): IARC; 2010. Available from: http://globocan.iarc.fr. 2010
2. China MoHotPsRo. China Health Statistical Yearbook 2012. Mortality Rate of 10 Main Malignant Neoplasms From 2004 to 2005 (1/100 000). Peking (China): Peking Union Medical College Press; 2012.
3. Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res 2013 161: 355-364.
4. Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010; 21: 185-195.
5. Nuesch JP, Lacroix J, Marchini A, Rommelaere J. Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment. Clin Cancer Res 2012; 18: 3516-3523.
6. Lachmann S, Rommeleare J, Nuesch JP. Novel PKCeta is required to activate replicative functions of the major nonstructural protein NS1 of minute virus of mice. J Virol 2003; 77: 8048-8060.
7. Bar S, Rommelaere J, Nuesch JP. Vesicular transport of progeny parvovirus particles through ER and Golgi regulates maturation and cytolysis. PLoS Pathog 2013; 9: e1003605.
8. Nuesch JP, Rommelaere J. NS1 interaction with CKII alpha: novel protein complex mediating parvovirus-induced cytotoxicity. J Virol 2006; 80: 4729-4739.
9. Lacroix J, Schlund F, Leuchs B, Adolph K, Sturm D, Bender S, et al. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. Int J Cancer 2014; 134: 703-716.
10. Nuesch JP, Lachmann S, Rommelaere J. Selective alterations of the host cell architecture upon infection with parvovirus minute virus of mice. Virology 2005; 331: 159-174.
11. Bar S, Daeffler L, Rommelaere J, Nuesch JP. Vesicular egress of non-enveloped lytic parvoviruses depends on gelsolin functioning. PLoS Pathog 2008; 4: e1000126.
12. Nuesch JP, Rommelaere J. A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells. Proc Natl Acad Sci U S A 2007; 104: 12482-12487.
13. Hristov G, Kramer M, Li J, El-Andaloussi N, Mora R, Daeffler L, et al. Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species. J Virol 2010; 84: 5909-5922.
14. Lachmann S, Bar S, Rommelaere J, Nuesch JP. Parvovirus interference with intracellular signalling: mechanism of PKCeta activation in MVM-infected A9 fibroblasts. Cell Microbiol 2008; 10: 755-769.
15. Grekova S, Aprahamian M, Giese N, Schmitt S, Giese T, Falk CS, et al. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biol Ther 2011; 10: 1280-1289.
16. Bhat R, Dempe S, Dinsart C, Rommelaere J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer 2011; 128: 908-919.
17. Wang YY, Liu J, Zheng Q, Ran ZH, Salome N, Vogel M, et al. Effect of the parvovirus H-1 non-structural protein NS1 on the tumorigenicity of human gastric cancer cells. J Dig Dis 2012; 13: 366-373.
18. Nakashima A, Morita E, Saito S, Sugamura K. Human Parvovirus B19 nonstructural protein transactivates the p21/WAF1 through Sp1. Virology 2004; 329: 493-504.
19. Shirota T, Kasuya H, Kodera Y, Nishikawa Y, Shikano T, Sahin TT, et al. Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer. Hepatogastroenterology 2011; 58: 1482-1489.
20. Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, et al. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus. Cancer Biol Ther 2010; 10: 242-250.
21. Thirukkumaran C, Morris DG. Oncolytic viral therapy using reovirus. Methods Mol Biol 2009; 542: 607-634.
22. Muharemagic D, Labib M, Ghobadloo SM, Zamay AS, Bell JC, Berezovski MV. Anti-Fab aptamers for shielding virus from neutralizing antibodies. J Am Chem Soc 2012; 134: 17168-17177.
23. Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 2012; 72: 1621-1631.
24. Ventoso I, Berlanga JJ, Almendral JM. Translation control by protein kinase R restricts minute virus of mice infection: role in parvovirus oncolysis. J Virol 2010; 84: 5043-5051.
25. Grekova S, Zawatzky R, Horlein R, Cziepluch C, Mincberg M, Davis C, et al. Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism. J Virol 2010; 84: 516-531.